Top
Relapsed or Refractory Multiple Myeloma - Healing Genes
1368
post-template-default,single,single-post,postid-1368,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Relapsed or Refractory Multiple Myeloma

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma


Phase 1

DESCRIPTION:

Researchers in 8 states seek patients with multiple myeloma to trial an autologous (to the self) T-cell infusion after those cells are gene-modified to target tumors. The investigatory treatment gene-modifies the patient’s own immune T-cells to recognize and kill myeloma tumor cells. This will require leukapheresis to collect the T-cells, which are gene-modified in the lab before being returned to the patient. Antibody treatments called SEA-BCMA against specific myeloma antigens will also be given.

Follow up to assess the safety and effectiveness of the combination of tumor-targeting treatments will be required for at least 52 weeks..


PATIENT MUST:

  • Be 18 to 80 years of age
  • Have histologically- or cytologically-confirmed relapsed or refractory multiple myeloma (MM) with measurable disease meeting clinical criteria for past treatments
  • Have a life expectancy of 6 months or greater
  • Not have known active central nervous system (CNS) involvement by multiple myeloma

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Leukapheresis to isolate T-cells which are then modified in the lab.
  3. The modified T cells will be given into the vein through an IV line.
  4. SEA-BCMA antibody therapy will be infused.
  5. Follow up to assess the safety and effectiveness of the drug to reduce the tumor will be required for at least a year.

LOCATIONS & CONTACTS:
The study sites are:
Mayo Clinic in Phoenix, AZ, Map.
 
Mayo Clinic in Jacksonville, FL, Map.
Indiana Bone and Marrow Transplantation in Indianapolis, IN, Map.
Tufts Medical Center in Boston, MA, Map.
Ohio State University Wexner Medical Center in Columbus, OH, Map.
Baylor Scott & White in Dallas, TX, Map.
Medical College of Wisconsin in Milwaukee, WI, Map.
 
Contacts:
Iga Sienczylo  |  617-945-5576 ext 238  |  [email protected]
Jessica Sachs, MD  |  617-286-6604  |  [email protected]
 
SPONSORS
Unum Therapeutics Inc.
Seattle Genetics, Inc.
 
Or go online:
https://clinicaltrials.gov/ct2/show/NCT03266692

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader